Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Apr;84(1):1–8. doi: 10.1111/j.1365-2249.1991.tb08115.x

The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.

Y M Lucisano Valim 1, P J Lachmann 1
PMCID: PMC1535367  PMID: 1707767

Abstract

A systematic study has been carried out to investigate the role of immunoglobulin isotype, epitope density, and antigen/antibody ratio on the capacity of immune complexes to activate the classical and alternative pathways of human complement and for the complexes subsequently to bind to erythrocyte C3b-C4b receptors (CRI). For this purpose, a series of chimaeric monoclonal anti-NIP antibodies was used, which all shared the same combining site but had different human constant domains. Antigen epitope density was varied by coupling different numbers of NIP hapten molecules to bovine serum albumin. All three parameters affect complement fixation. In general, complement activation is better in antibody excess and at equivalence than it is in antigen excess, and better at high epitope density than at low epitope density, although the effects are variable for different immunoglobulin isotypes and for the two pathways. It has been confirmed that IgG1 and IgG3 are good activators of the classical pathway and are tolerant to variations in both epitope density and antigen/antibody ratio. IgG4 and IgA do not activate the classical pathway in any circumstances. IgG2 activates the classical pathway only at high epitope density and at equivalence or antibody excess. IgM activates the classical pathway well only at the higher epitope densities and at equivalence or antibody excess but, in addition, shows an interesting and unexpected prozone phenomenon where immune complex in antibody excess inhibits complement activation by the classical pathway. The results of the alternative pathway activation are strikingly different. IgA is by far the best activator of the alternative pathway and is relatively tolerant to epitope density and to antigen/antibody ratio. IgM, IgG1 and IgG3 do not significantly activate the alternative pathway in any circumstances. IgG2 is the best IgG subclass for alternative pathway activation but requires high epitope density and equivalence or antibody excess. Binding to CR1 in general parallels the amount of complement fixed independent to the pathway by which it is fixed. However, IgG1 and IgG3 complexes in antigen excess activate complement well but bind poorly to CR1. Nascently formed complexes seem to bind complement in a way that is similar to that bound by preformed complexes, but are then less able to bind to red cell CR1. These observations help to explain the pathogenesis of complement activation in various autoimmune and immune complex diseases such as systemic lupus erythematosus, autoimmune thyroiditis and others.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brüggemann M., Williams G. T., Bindon C. I., Clark M. R., Walker M. R., Jefferis R., Waldmann H., Neuberger M. S. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987 Nov 1;166(5):1351–1361. doi: 10.1084/jem.166.5.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cornacoff J. B., Hebert L. A., Birmingham D. J., Waxman F. J. Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptor. Clin Immunol Immunopathol. 1984 Feb;30(2):255–264. doi: 10.1016/0090-1229(84)90060-6. [DOI] [PubMed] [Google Scholar]
  3. Cornacoff J. B., Hebert L. A., Smead W. L., VanAman M. E., Birmingham D. J., Waxman F. J. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest. 1983 Feb;71(2):236–247. doi: 10.1172/JCI110764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cosio F. G., Hebert L. A., Birmingham D. J., Dorval B. L., Bakaletz A. P., Kujala G. A., Edberg J. C., Taylor R. P. Clearance of human antibody/DNA immune complexes and free DNA from the circulation of the nonhuman primate. Clin Immunol Immunopathol. 1987 Jan;42(1):1–9. doi: 10.1016/0090-1229(87)90167-x. [DOI] [PubMed] [Google Scholar]
  5. FARR R. S. A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J Infect Dis. 1958 Nov-Dec;103(3):239–262. doi: 10.1093/infdis/103.3.239. [DOI] [PubMed] [Google Scholar]
  6. Hebert L. A., Cosio G. The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int. 1987 Apr;31(4):877–885. doi: 10.1038/ki.1987.81. [DOI] [PubMed] [Google Scholar]
  7. Hiemstra P. S., Biewenga J., Gorter A., Stuurman M. E., Faber A., van Es L. A., Daha M. R. Activation of complement by human serum IgA, secretory IgA and IgA1 fragments. Mol Immunol. 1988 Jun;25(6):527–533. doi: 10.1016/0161-5890(88)90074-0. [DOI] [PubMed] [Google Scholar]
  8. Hiemstra P. S., Gorter A., Stuurman M. E., Van Es L. A., Daha M. R. Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol. 1987 Mar;17(3):321–326. doi: 10.1002/eji.1830170304. [DOI] [PubMed] [Google Scholar]
  9. Kávai M., Rasmussen J. M., Baatrup G., Zsindely A., Svehag S. E. Inefficient binding of IgM immune complexes to erythrocyte C3b-C4b receptors (CR1) and weak incorporation of C3b-iC3b into the complexes. Scand J Immunol. 1988 Jul;28(1):123–128. doi: 10.1111/j.1365-3083.1988.tb02423.x. [DOI] [PubMed] [Google Scholar]
  10. Lachmann P. J. Complement deficiency and the pathogenesis of autoimmune immune complex disease. Chem Immunol. 1990;49:245–263. [PubMed] [Google Scholar]
  11. Lachmann P. J. Heberden oration 1986. Complement--friend or foe? Br J Rheumatol. 1987 Dec;26(6):409–415. doi: 10.1093/rheumatology/26.6.409. [DOI] [PubMed] [Google Scholar]
  12. Lachmann P. J., Hughes-Jones N. C. Initiation of complement activation. Springer Semin Immunopathol. 1984;7(2-3):143–162. doi: 10.1007/BF01893018. [DOI] [PubMed] [Google Scholar]
  13. McConahey P. J., Dixon F. J. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol. 1966;29(2):185–189. doi: 10.1159/000229699. [DOI] [PubMed] [Google Scholar]
  14. Medgyesi G. A., Miklós K., Kulics J., Füst G., Gergely J., Bazin H. Classes and subclasses of rat antibodies: reaction with the antigen and interaction of the complex with the complement system. Immunology. 1981 May;43(1):171–176. [PMC free article] [PubMed] [Google Scholar]
  15. Platts-Mills T. A., Ishizaka K. Activation of the alternate pathway of human complements by rabbit cells. J Immunol. 1974 Jul;113(1):348–358. [PubMed] [Google Scholar]
  16. Ratnoff W. D., Fearon D. T., Austen K. F. The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol. 1983;6(4):361–371. doi: 10.1007/BF02116280. [DOI] [PubMed] [Google Scholar]
  17. Reid K. B. Complement fixation by the F(ab')2-fragment of pepsin-treated rabbit antibody. Immunology. 1971 May;20(5):649–658. [PMC free article] [PubMed] [Google Scholar]
  18. Sandberg A. L., Oliveira B., Osler A. G. Two complement interaction sites in guinea pig immunoglobulins. J Immunol. 1971 Jan;106(1):282–285. [PubMed] [Google Scholar]
  19. Schifferli J. A., Ng Y. C., Estreicher J., Walport M. J. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J Immunol. 1988 Feb 1;140(3):899–904. [PubMed] [Google Scholar]
  20. Schifferli J. A., Ng Y. C., Paccaud J. P., Walport M. J. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol. 1989 Mar;75(3):329–335. [PMC free article] [PubMed] [Google Scholar]
  21. Schifferli J. A., Ng Y. C., Peters D. K. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med. 1986 Aug 21;315(8):488–495. doi: 10.1056/NEJM198608213150805. [DOI] [PubMed] [Google Scholar]
  22. Schifferli J. A., Taylor R. P. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989 Apr;35(4):993–1003. doi: 10.1038/ki.1989.83. [DOI] [PubMed] [Google Scholar]
  23. Steward M. W., Petty R. E. The use of ammonium sulphate globulin precipitation for determination of affinity of anti-protein antibodies in mouse serum. Immunology. 1972 May;22(5):747–756. [PMC free article] [PubMed] [Google Scholar]
  24. Varga L., Thiry E., Füst G. BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells. Immunology. 1988 Jul;64(3):381–384. [PMC free article] [PubMed] [Google Scholar]
  25. Waller S. J., Taylor R. P., Wright E. L., Morley K. W., Johns M. DNA/anti-DNA complexes: correlation of size and complement fixation. Arthritis Rheum. 1981 May;24(5):651–657. doi: 10.1002/art.1780240504. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES